The value of influenza and pneumococcal vaccines in the elderly

Drugs and Aging

Volumn 8, Issue 6, 1996, Pages 445-451

  Monto, Arnold S ^a   Terpenning, Margaret S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

COST CONTROL; DRUG EFFICACY; DRUG USE; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; INFLUENZA; PHARMACOECONOMICS; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS INFECTION;

EID: 0029900553     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199608060-00006     Document Type: Review

References (34)

1. Serfling RE, Sherman IL, Housworth WJ. Excess pneumonia-influenza mortality by age and sex in three major influenza A2 epidemics. United States, 1957-58, 1960, and 1963. Am J Epidemiol 1967; 86: 433-41
2. Fiebach N, Beckett W. Prevention of respiratory infections in adults: influenza and pneumococcal vaccines. Arch Intern Med 1994; 154: 2545-57
3. Perez-Tirse J, Gross PA. Review of cost-benefit analyses of influenza vaccine. PharmacoEconomics 1992; 2: 198-206
4. Butler JC, Brieman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. JAMA 1993; 270: 1826-31
5. Strassburg MA, Greenland S, Sorvillo FJ, et al. Influenza in the elderly: report of an outbreak and a review of vaccine effectiveness reports. Vaccine 1986; 4: 38-44
6. Coles FB, Balzano GJ, Morse DL. An outbreak of influenza A(H3N2) in a well immunized nursing home population. J Am Geriatr Soc 1992; 40: 589-92
7. Phair J, Kauffman CA, Bjornson A, et al. Failure to respond to influenza vaccine in the aged: correlation with B-cell number and function. J Lab Clin Med 1978; 92: 822-8
8. Patriarca PA, Weber JA, Parker RA, et al. Efficacy of influenza vaccine in nursing homes: reduction in illnesses and complications during an influenza A (H3N2) epidemic. JAMA 1985; 253: 1136-9
9. Office of Technology Assessment, US Congress. Cost effectiveness of influenza vaccination. Washington, DC: Government Printing Office, 1982
10. Meitl JF. Influenza immunization for Medicare eligibles: a demonstration of cost-effectiveness. Twenty-second Immunization Conference Proceedings. Atlanta (GA): United States Department of Health and Human Services. Public Health Services, 1988: 117-8
11. McBean AM, Babish JD, Warren JL. The impact and cost of influenza in the elderly. Arch Intern Med 1993; 153: 2105-11
12. Foster DA, Talsma A, Furumoto-Dawson A, et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 1992; 136: 296-307
13. Ohmit SE, Monto AS. Influenza vaccine effectiveness in preventing hospitalization among the elderly during influenza type A and type B seasons. Int J Epidemiol 1995; 24: 1240-8
14. Centers for Disease Control. Final results: Medicare influenza vaccine demonstration - selected states, 1988-1992. MMWR Morbid Mortal Wkly Rep 1993; 42: 601-4
15. Fedson DS, Wajda A, Nicol JP, et al. Clinical effectiveness of influenza vaccine in Manitoba. JAMA 1993; 270: 1956-61
16. Nichol KL, Margolis KL, Wuorenma H, et al. The efficacy and cost-effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331: 778-84
17. Mullooly JP, Bennett MD, Hornbrook MC, et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994; 121: 947-52
18. Mucher DM, Watson DA, Dominguez EA. Pneumococcal vaccination: work to date and future prospects. Am J Med Sci 1990; 300: 45-52
19. Heffron R. Pneumonia with special reference to pneumococcus lobar pneumonia. New York: The Commonwealth Fund. 1939: 446-78
20. Fedson DS, Wajda A, Nicol JP, et al. The old man's friend [letter]. Lancet 1993; 342: 561
21. Austrian R, Douglas RM, Schiffman G. et al. Prevention of pneumonia by vaccination. Trans Assoc Am Phys 1976; 89: 184-94
22. Kerttula Y, Leinonen M, Koskela M, et al. The aetiology of pneumonia: application of bacterial serology and basic laboratory methods. J Infect 1987; 14: 21-30
23. Austrian R. A reassessment of pneumococcal vaccine. N Engl Med 1984; 310: 651-3
24. Clemens JD, Shapiro ED. Resolving the pneumococcal vaccine controversy: are there alternatives to randomized clinical trials? Rev Infect Dis 1984; 6: 589-99
25. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325: 1453-60
26. LaForce FM, Eickhoff TC. Pneumococcal vaccine: an emerging consensus. Ann Intern Med 1988; 108: 757-9
27. Forrester HL, Jahnigen DW, LaForce FM. Inefficacy of pneumococcal vaccine in a high-risk population. Am J Med 1987; 83: 425-30
28. Borgono JM, McLean AA, Veil PP, et al. Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants. Proc Soc Exp Biol Med 1978; 157: 148-54
29. Centers for Disease Control and Prevention. Pneumococcal polysaccharide vaccine. MMWR Morb Mortal Wkly Rep 1989; 38: 64-76
30. Sisk JF, Riegelman RK. Cost effectiveness of vaccination against pneumococcal pneumonia: an update. Ann Intern Med 1986; 104: 79-86
31. McBean AM, Babish JD, Prihoda R. The utilization of pneumococcal polysaccharide vaccine among elderly Medicare beneficiaries. 1985 through 1988. Arch Intern Med 1991; 151: 2009-16
32. Gable CB, Holzer SS, Engelhart L, et al. Pneumococcal vaccine: efficacy and associated cost savings. JAMA 1990; 264: 2910-5
33. DeStefano F, Goodman RT, Noble GR, et al. Simultaneous administration of influenza and pneumococcal vaccine. JAMA 1982; 247: 2551-4
34. Applebaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis 1992; 15: 77-83